Coherus Oncology, Inc. (CHRS)
| Market Cap | 78.18M -45.6% |
| Revenue (ttm) | 53.64M +44.4% |
| Net Income | -135.94M |
| EPS | -0.96 |
| Shares Out | 154.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,648,825 |
| Open | 0.5130 |
| Previous Close | 0.5255 |
| Day's Range | 0.4786 - 0.5275 |
| 52-Week Range | 0.4786 - 2.6160 |
| Beta | 1.05 |
| Analysts | Buy |
| Price Target | 7.25 (+1,333.09%) |
| Earnings Date | Nov 9, 2026 |
About CHRS
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibo... [Read more]
Financial Performance
In 2025, Coherus Oncology's revenue was $42.17 million, an increase of 59.81% compared to the previous year's $26.39 million. Earnings were $168.02 million, an increase of 489.41%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CHRS stock is "Buy." The 12-month stock price target is $7.25, which is an increase of 1,333.09% from the latest price.
News
Coherus Oncology Transcript: Jefferies Global Healthcare Conference
Tagmokitug’s early esophageal data showed 89% ORR in 9 patients, including 100% among PD-L1-positive patients, and the planned next step is an FDA discussion on second-line development. LOQTORZI sales were about $14 million for the quarter, with 2027 growth targets outlined.
Oncolytics enters clinical supply agreement with Coherus Oncology
Oncolytics (ONCY) announced that it has entered into a clinical supply agreement with Coherus Oncology (CHRS) to evaluate Oncolytics’ investigational oncolytic virus immunotherapy, pelareorep, in comb...
Coherus Oncology Slides: Corporate presentation
Coherus Oncology has posted slides in relation to its latest quarterly earnings report, which was published on November 11, 2026.
Coherus Oncology reports Q3 EPS (20c), consensus (21c)
Reports Q3 revenue $14.27M, consensus $15.93M. “The strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down...
Coherus Oncology price target lowered to $8 from $10 at Guggenheim
Guggenheim lowered the firm’s price target on Coherus Oncology (CHRS) to $8 from $10 and keeps a Buy rating on the shares after updating the firm’s model for Q3 results…
Coherus Oncology Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Development is concentrating on second-line esophageal cancer after promising tagmokitug activity, with FDA discussions planned in early 2027. Cost reductions and LOQTORZI growth are intended to move core operations toward break-even.
Coherus Oncology Earnings Call Transcript: Q3 2026
Q3 LOQTORZI sales were $14M, up 25% YoY, while full-year revenue guidance was reset to $54M-$57M. A 30% workforce reduction is expected to save $6M-$7M quarterly, and development is refocused on tagmokitug in esophageal cancer.
Coherus Oncology Earnings release: Q3 2026
Coherus Oncology released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Coherus Oncology Quarterly report: Q3 2026
Coherus Oncology has published its Q3 2026 quarterly earnings report on November 9, 2026.
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development –
Coherus Oncology assumed with a Buy at H.C. Wainwright
H.C. Wainwright assumed coverage of Coherus Oncology (CHRS) with a Buy rating and $7 price target The company’s Loqtorzi remains the only FDA-approved and available treatment for recurrent or metastat...
Coherus Oncology announces clinical data from TREGCHECK development program
Coherus Oncology (CHRS) announced interim clinical data from the TREGCHECK development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with...
Coherus Oncology Transcript: Study result
Interim TREGCHECK data showed a 75% first-line ESCC ORR at cutoff, rising to 89% with later scans, and dose-related activity in second-line ESCC and other tumors. Follow-up and enrollment will expand to support development plans.
Coherus Oncology Press release: Study result
Coherus Oncology issued a press release on October 28, 2026, disclosing material business information to investors.
Coherus Oncology Slides: Study result
Coherus Oncology has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
- 1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irr...
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor ...
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 202...
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development ...
Coherus Oncology retains Oppenheimer to market legacy biosimilar assets
Coherus Oncology (CHRS) has initiated the process to market and sell the remaining assets associated with the Company’s former biosimilars business. The Company has retained Oppenheimer & Co. to serve...
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - - Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -
Coherus Oncology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
LOQTORZI is gaining traction in the nasopharyngeal cancer market, with strong sales growth and a clear path to profitability. The pipeline features promising assets like Tagmokitug for multiple tumor types and casdozokitug for HCC, both showing encouraging early data and a focus on biomarker-driven development.
Coherus Oncology Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The company has fully transitioned to innovative oncology, with LOQTORZI driving revenue growth and funding a robust pipeline. Key assets tagmokitug and casdozokitug are advancing in trials, with major data updates expected in October and year-end, supported by a strong cash position.
Coherus Oncology Transcript: 2026 Global Healthcare Conference
Development priorities are tagmokitug across six indications, casdozokitug in first-line HCC, and LOQTORZI growth in nasopharyngeal cancer. Key readouts are expected in October and toward year-end 2026, with LOQTORZI sales projected to help cover core costs in 2027.
Coherus Oncology issuing special dividend of biosimilar contingent value rights
Coherus Oncology (CHRS) announced a special dividend of contingent value rights which will be distributed on a pro rata basis to stockholders of record as of September 30. The distribution…